Karyopharm Therapeutics (KPTI)
(Delayed Data from NSDQ)
$1.06 USD
0.00 (0.00%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.05 -0.01 (-0.94%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Price, Consensus and EPS Surprise
KPTI 1.06 0.00(0.00%)
Will KPTI be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for KPTI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for KPTI
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates
Xencor (XNCR) Surges 13.4%: Is This an Indication of Further Gains?
KPTI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ardelyx (ARDX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Will Karyopharm Therapeutics (KPTI) Report Negative Q4 Earnings? What You Should Know
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates
Other News for KPTI
Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting
Karyopharm Therapeutics (KPTI) Gets a Buy from Piper Sandler
Analysts Are Bullish on Top Healthcare Stocks: Ionis Pharmaceuticals (IONS), Intuitive Surgical (ISRG)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Onco360 Selected as the Preferred National Specialty Pharmacy Partner for XPOVIO® (selinexor)